CG Oncology Announced Updated Data On BOND-003 Cohort C Showing 12 Additional Patients With High Risk Non-muscle Invasive Bladder Cancer Were In Complete Response At 24 Months, With Complete Response Rate Of 41.8%
Benzinga Newsdesk 1 year ago
BiotechHealth CareGeneral
Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG)
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment.
- 90% of 12-month responders remained disease free at 24 Months.
- Safety profile remains consistent -